#### <sup>1</sup>**Title: Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a**

## <sup>2</sup>**proclivity for immune-privileged organ-tropism**

3



- 25
- 

- **Running Title:** Molecular landscape in primary renal DLBCL
- **Key Words:** PR-DLBCL, molecular landscape, immune-privileged site, MHC Class I and II
- **Word Count (Abstract): 200**
- **Word Count (Text): 3.782**
- **References: 57**
- **Figures: 6**
- **Supplementary Tables: 8**
- **Supplemental Figures: 4**
- **Supplementary References: 9**
- **Competing Interests:** Niklas Gebauer received travel support from Beigene, Janssen, and
- Roche as well as honoraria from Roche, Takeda, Janssen, Menarini Stemline, and
- 38 AstraZeneca.
- 
- 40 \*These authors contributed equally to this manuscript.
- 41 \*\*Shared senior authorship
- **Date of submission: 28.06.2024**
- 
- **Corresponding Author:**
- PD Dr. med. Niklas Gebauer
- 46 Department of Hematology and Oncology
- UKSH Campus Luebeck
- 48 Ratzenburger Allee 160
- 23538 Luebeck
- Email: Niklas.Gebauer@uksh.de

# <sup>52</sup>**Abstract:**

53 Primary renal manifestations of diffuse large B-cell lymphoma (PR-DLBCL) represent an 54 exceptionally rare variant of the most common type of non-Hodgkin lymphoma (NHL). <sup>55</sup>Insights into PR-DLBCL pathogenesis have been limited to small case series and <sup>56</sup>methodologically limited approaches. The mechanisms driving lymphomagenesis within an 57 organ lacking an intrinsic lymphatic niche and its proclivity for dissemination to immune-58 privileged sites, including testes and central nervous system, remain poorly understood. To 59 decode the genetic and transcriptional framework of PR-DLBCL, we utilized whole exome 60 sequencing, array-based somatic copy number alterations analysis, and RNA sequencing. 61 Hereby we characterize the most extensive cohort of PR-DLBCL published, comprising 34 62 samples from 30 patients. Despite significant mutational heterogeneity with a broad 63 distribution among molecular clusters, we observed a strong unifying enrichment in 64 deleterious MHC class I and II aberrations and loss of *CDKN2A* at a frequency similar to 65 primary large B-cell lymphoma of immune privileged sites (IP-LBCL) alongside significant 66 transcriptional deregulation of interferon signaling and MYC targets in MHC class I-deficient 67 cases.

68 Our integrative assessment of PR-DLBCL biology expands the molecular understanding of 69 this rare variant including similarities with IP-LBCL as an intriguing explanation for its 70 clinical behavior and tropism. Our observations may inform future risk-adapted therapeutic 71 approaches.

#### <sup>73</sup>**Introduction:**

<sup>74</sup>Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin 75 lymphoma (NHL) and accounts for  $30 - 40\%$  of newly diagnosed lymphomas <sup>1</sup>. Extranodal <sup>76</sup>manifestations in both the adrenal glands and the kidneys constitute long-standing risk factors 77 for developing simultaneous or secondary  $CNS$  manifestations  $2$ . Secondary renal

78 involvement is recurrently observed in advanced-stage non-Hodgkin lymphoma (NHL), <sup>79</sup>whereas primary renal (PR-) NHL manifestations are notably less frequent, leading to 80 skepticism regarding the existence of primary renal lymphoma for an extended period  $2-6$ . 81 Population-based datasets suggest an age-adjusted incidence of 0.035/100,000 with an 82 increasing tendency, a median age of approximately 70 years at diagnosis, a male 83 predominance, and mostly unilateral tumors. Among PR-NHL, DLBCL appears to be the 84 most common histology followed by marginal zone (MZL) and follicular lymphoma (FL)  $^{7, 8}$ . <sup>85</sup>Clinical differentiation of PR-NHL from other renal malignancies including renal cell 86 carcinoma poses a long-standing challenge, which led to a substantial number of PR-NHL 87 patients undergoing curatively intended resection <sup>9</sup>. In recent years, the introduction of FDG-<sup>88</sup>PET-CTs into routine clinical practice has enabled a more reliable characterization, 89 particularly in patients with more aggressive PR-NHL $^{10}$ .

90 Insufficient characterization of pathogenetic mechanisms in indolent PR-DLBCL derives 91 from limited data, primarily comprised of small case series and a lack of in-depth molecular 92 characterization of patients and samples  $<sup>11</sup>$ . Molecular drivers of lymphomas originating from</sup> 93 organs lacking an intrinsic lymphatic niche, such as the kidney, remain widely elusive apart 94 from individual case studies  $^{12}$ . To elucidate the genetic and transcriptional landscape and 95 drivers of PR-DLBCL, we conducted a comprehensive investigation employing whole exome 96 sequencing (WES), array-based analysis of somatic copy number alterations (SCNA), and 97 RNA sequencing (RNA-seq) to unravel both molecular properties of this rare entity as well as 98 the cellular composition of its tumor microenvironment (TME).

99

#### <sup>100</sup>**Materials and methods**

#### <sup>101</sup>**Case selection and clinicopathological assessment**

<sup>102</sup>For this retrospective analysis, we reviewed our institutional archive for cases of 103 histologically confirmed primary renal DLBCL between January 2001 and December 2021.

<sup>104</sup>Only such cases without concurrent non-renal lymphoma manifestations at diagnosis were 105 included in the study, which led to a large subset of samples obtained by complete renal 106 resection under the suspicion of non-metastatic renal cell carcinoma (22/34 samples; 65%). 107 The study was approved by the ethics committee of the University of Lübeck (reference-no <sup>108</sup>18-356) and conducted per the declaration of Helsinki. Patients provided written informed 109 consent regarding routine diagnostic and academic assessment, including genomic studies. <sup>110</sup>Histopathological work-up was performed as described and diagnosis was confirmed following the  $5<sup>th</sup>$  edition WHO classification of hematopoietic and lymphoid tumors and the 112 ICC criteria and yielded 34 cases of PR-DLBCL for which sufficient formalin-fixed paraffin-113 embedded (FFPE) tissue samples were available for subsequent molecular analysis  $1, 13, 14$ .

#### <sup>115</sup>**Delineation of the molecular composition of the study cohort**

116 Extraction of nucleic acids, WES and RNA-seq alongside detection of Somatic Copy Number

117 Alterations employing the OncoScan CNV array (ThermoFisher was performed as described,

118 and Raw fastq files have been added to the European Genome-phenome archive (EGA) under

119 the previous accession number EGA50000000386<sup> $13, 15$ </sup>. OncoScan Array data has been

120 deposited in Gene Expression Omnibus (GEO) under accession number GSE270422.

#### <sup>122</sup>**Whole exome data processing and variant calling**

123 The raw sequencing data in FASTQ format was processed using the NFORE workflow <sup>124</sup>(NEXTFLOW v23.10.1) SAREK (v3.3.2) for variant calling against the GRCh38 reference 125 genome  $16, 17$ . Initially, reads were trimmed for adapter sequences and quality using FASTP 126 (v0.23.4), followed by alignment with BWA MEM2 (v2.2.1)<sup>18, 19</sup>. Subsequent steps included 127 mate-pair information correction, removal of PCR duplicates, and base quality recalibration 128 utilizing PICARD TOOLS, GATK (v4.4.0.0), and dbSNP v146<sup>20, 21</sup>. Finally, variant calling was 129 executed in tumor-only mode using MUTECT2 with GNOMAD  $(r2.1.1)$  as the reference for

130 known germline variants  $22, 23$ . Variants were left aligned (GATK 131 LEFTALIGNANDTRIMVARIANTS) and only variants with a PASS filter flag were kept for 132 variant annotation using VARIANT EFFECT PREDICTOR (VEP v111, GRCh38; adding CADD 133 v1.6, dbNSFP v4.1a, and GNOMAD r3.0 as additional annotations)  $^{24-26}$ . Next, annotations 134 were converted into *MAF* format using VCF2MAF (V1.6.21) <sup>135</sup>(DOI:10.5281/ZENODO.593251); coverage was extracted directly from the vcf INFO field.

136 Potential FFPE artifacts in the variant data were identified using two approaches. First, strand 137 orientation biases (mutations just found on one strand, F1R2 or F2R1) were detected by 138 SOBDETECTOR (v1.0.4) and potential artifacts were removed  $^{27}$ . Next, a classifier detecting 139 the origin of mutation in formalin-fixation paraffin-embedding (FFPE) samples was applied 140 (R-package EXCERNO v0.1.0)<sup>28</sup>. Variants annotated with an FFPE-like signature were 141 removed. Potential germline variants in the data were removed using GATKs 1000g Panel of 142 Normals. The top 20 frequently mutated genes  $(FLAGS)^{29}$  were removed from further 143 analysis and the remaining somatic variants were filtered as follows: minimum coverage of 144 50, minimum alternative allele coverage of 5, minimum variant allele frequency of 10%, and 145 only variants with a frequency  $< 0.1\%$  in 1000 genomes, GNOMAD, or ExAC were 146 considered for subsequent downstream analysis; variants were required to have a COSMIC or 147 dbSNP ID. High-impact variants (CADD score  $> 20$ ) in candidate genes (see below) were 148 filtered as such that minimum coverage of 10, minimum alternative coverage of 4, and 149 minimum variant allele frequency of 10% was required. Candidate genes were defined as 150 follows: (a) listed as tumor suppressor or oncogene according to Vogelstein et al.  $^{30}$ , (b) genes 151 from the Lymphgen algorithm, (c) DLBCL genes described by Chapuy *et al.*, (d) MHC genes 152 according to Harmonizome (v3.0)  $31-33$ . A brief graphical representation of the bioinformatics 153 workflow for WES data processing is provided in **Supplementary Figure S1**.

## <sup>155</sup>**Detection of Somatic Copy Number Alterations**

156 Somatic copy number alterations were detected using OncoScan CNV assays (ThermoFisher). 157 Raw data (CEL files) were processed using the EACON package (v0.3.6-2) with SEQUENZA 158 as segmentation algorithm <sup>34</sup>. L2R files in CBS format were used as input for GISTIC  $159$  (v2.0.22) to identify regions significantly amplified or deleted across all samples (confidence 160 level 0.90, focal length cutoff 0.5, q-value threshold 0.1)  $^{34, 35}$ . 162 For details on transcriptome data quantification, fusion detection, statistical analysis, and

<sup>163</sup>pseudonymization, please see **Supplementary Materials and Methods**.

164

<sup>165</sup>**Results** 

# <sup>166</sup>**Clinicopathological Characteristics and Cell-of-Origin in PR-DLBCL**

<sup>167</sup>We collected 34 PR-DLBCL samples from 30 patients with sufficient FFPE tissue samples 168 for in-depth molecular characterization (**Figure 1A**). The median age of the study group was <sup>169</sup>66.5 years, 13 patients were female and 17 were male. No iatrogenic immunosuppression, 170 immunodeficiency, and history or current presence of other lymphomas were reported in any 171 of the patients. In particular, only patients without suspicion of concurrent lymphoma 172 manifestations were eligible for the study. This is mirrored in the exceptionally high 173 frequency of cases that underwent surgical resection of the kidney (22/34 cases; 65%).

<sup>174</sup>Baseline clinicopathological data are summarized in **Supplementary Table 1**.

175 Structural variants in *BCL2*, *BCL6*, and *MYC* were assessed successfully in 19, 18, and 17 176 patients by FISH break-apart probes. In cases without sufficient tissue for FISH but with <sup>177</sup>RNA-seq data, we screened for high-confidence *BCL2/BCL6/MYC* fusions (**Figure 1 B**). 178 Here, we observed aberrations in five  $(26 \%)$ , two  $(11 \%)$ , and three  $(18\%)$  cases respectively, 179 indicative of a slightly elevated frequency of these aberrations in comparison to DLBCL <sup>180</sup>(NOS) of other primary manifestations. In addition, we observed two cases with ETV6-Ig

181 fusions, previously described in PCNSL another case of an ETV6:PAX5 fusion respectively, 182 previously described to lead to similar ETV6 activation in B-cell precursor acute 183 lymphoblastic leukemia  $36, 37$ . Manually curated oncogenic fusions derived from RNA-seq 184 data are summarized in **Supplementary Table 2**. By immunohistochemistry according to the 185 Hans *et al.* algorithm in all samples with sufficient tissue available after DNA/RNA 186 extraction, we observed the majority of cases to be of non-GCB type (18/30; 60%), whereas 187 only a minor subset was of GCB type (11/30; 37%), and one case could not be classified due 188 to insufficient immunoreactivity  $38$ . Only one case was EBV-associated ( $>50\%$  positive tumor 189 cells by EBER-ISH). To further unravel the cell of origin, we performed RNA-seq on samples 190 from 30 patients and applied the approach proposed by Wright *et al.* and found 15/30 cases <sup>191</sup>(50%) to be of ABC-subtype. In comparison, 9/30 (30%) were GCB-DLBCL and six 192 remaining cases (20%) remained unclassifiable  $^{31, 39}$  (**Figure 1 C**).

#### <sup>194</sup>**The mutational landscape of PR-DLBCL**

195 To elucidate the mutational landscape of PR-DLBCL and to screen for mutational drivers of

196 the subgroup's peculiar tropism, we performed WES on FFPE tissue samples from 34 patients

<sup>197</sup>(**Figure 1 D**).

<sup>198</sup>Adhering to stringent variant filtering, outlined above, oncogenic mutations were identified in 199 all PR-DLBCL cases. In total 3,178 presumably deleterious mutations, affecting 1,388 genes 200 were observed. Additionally, 25,457 somatic copy number aberrations (SCNAs) were 201 detected. SNVs and indels comprised 11% of these mutations, of which 2,673 were missense <sup>202</sup>(84%), 333 nonsense (10%) and 70 indel mutations (2%). Mutations affecting splice sites 203 represented 3% of estimated somatic mutations and one of the observed mutations was a non-204 stop mutation (**Supplementary Table 3**). At an intermediate-low median tumor mutational 205 burden (TMB) of 2.45 mutations/Mb (range  $0.18 - 5.76$ ), we observed no cases of <sup>206</sup>microsatellite instability as could be expected in aggressive B-cell lymphomas. Variants per

207 variant class as well as variants per sample including information on variant subtypes are

# 208 provided in **Supplementary Figure S2.**

<sup>209</sup>The most commonly mutated genes included chromatin-remodeling genes *CREBBP* and <sup>210</sup>*KMT2D* both in 56% of cases with > 20% nonsense mutations, followed by NOTCH 211 signaling-associated genes *SPEN* and *NOTCH2* (both 50%) with nonsense mutations in 47% 212 and 18% respectively. Overall, we observed an enrichment in IL6/JAK/STAT3 signaling <sup>213</sup>mutations including *STAT3*, *PIM1*, and *MYD88*. While *STAT3* mutations were distributed 214 throughout the entire gene, we observed mutational impairment of pre-described hotspots in <sup>215</sup>*MYD88* and *PIM1* (all restricted to the kinase domain) (**Figure 2**). Other biological processes 216 targeted by deleterious mutations in PR-DLBCL included the epigenetic regulation of gene <sup>217</sup>expression (*SF3B1*, *KMT2D*, and *EZH2*), as well as B-cell receptor and RTK-RAS signaling <sup>218</sup>(*CARD11*, *PRDM1*, and *BRAF*). The distribution of mutation onto the candidate driver genes 219 referenced above is displayed in **Figure 2**. In a more global approach, we assessed the 220 impairment of key biological processes through an enrichment analysis of mutations against 221 previously described oncogenetic gene sets and against the IL6/JAK/STAT3 signaling 222 pathway (**Figure 3**)<sup>40</sup>. Hereby we uncovered a relatively wide distribution within a given set 223 (**Figure 3A**). Intriguingly, the most commonly affected gene sets included NOTCH, RTK-<sup>224</sup>RAS, and IL6/JAK/STAT signaling at 97%, 94%, and 91%, respectively (**Figure 3 B, C**). 225 Beyond this, we observed mutational impairment of PI3K signaling in 79% of cases, 226 suggesting a significant role in PR-DLBCL pathogenesis. Correlating information on cell of 227 origin and mutational patterns, we observed a statistically significant enrichment in mutations <sup>228</sup>affecting *TNFAIP3* and *PIM1* among non-GCB cases. *BCL2* rearranged cases showed <sup>229</sup>significantly more *DNMT1* and *SMARCA4* mutations (**Supplementary Figure S3**). We 230 additionally screened for recurrent mutations in canonical tumor suppressor genes (TSGs) and 231 found deleterious mutations in 33/34 (97%) cases. Among the most common targets, in 232 addition to *CREBBP* and *KMT2D*, we observed mutations in *TP53* in 15% of cases.

233

### <sup>234</sup>**Genome-wide analysis of somatic copy-number variations in primary renal DLBCL**

235 To unravel the genome-wide landscape of SCNA in PR-DLBCL, we analyzed 29 samples 236 successfully on the Illumina OncoScan array and subsequently employed GISTIC (v2.0.22) to 237 identify regions significantly amplified or deleted across all samples. Arguably the most 238 striking observation was a broad arm-level deletion spanning a large region on chromosome 6 239 in 48% of evaluable cases (**Figure 4A**). Candidate genes, previously implicated in lymphoma <sup>240</sup>pathogenesis located in this vast region included *PRDM1*, *NFKBIE*, *HLA-A*, *HLA-B*, and <sup>241</sup>*ARID1B*. Beyond this aberration, the genome-wide CNV landscape of PR-DLBCL is 242 dominated by CNVs affecting 3p12.1 and leading to copy number losses of VHL, SETD2, 243 and others (17%), 9p21.3 encompassing the region encoding for TSG *CDKN2A* (38%), as 244 well as the *NOTCH1* region at 9q34.3 (28%). Focal amplifications were observed at 1q23.1, 245 3p12.3, 3q29, and 22q11.23. Candidate genes among significant deletions and amplifications 246 are provided in **Supplementary Table 4** and **Figure 4B**. To assess the characteristics of PR-247 DLBCL in contrast to transcriptionally defined subtypes of DLBCL (ABC/GCB) and primary <sup>248</sup>CNS lymphoma (PCNSL) as well as primary testicular large B-cell lymphoma (PTLBL) 249 together representing the subgroup of primary large B-cell lymphomas of immune-privileged 250 sites. We conducted a comparative analysis drawing CNV data from two previously published 251 large-scale genome-wide studies (**Figure 4 C**)<sup>41, 42</sup>. Apart from a focal 3q29 amplification, 252 none of the previously reported copy number gains were observed at a significant level in our 253 cohort. At the same time and of particular interest, we observed strong similarities between <sup>254</sup>PR-DLBCL, PCNSL, and PTLBL regarding deletions at 6p21.33, 6q21, and 6q23.3. <sup>255</sup>Candidate gene deletions previously implicated in post-germinal differentiation and strong 256 CNS tropism located at these loci include *HLA-B* and *PRDM1*. Moreover, we identified the <sup>257</sup>above-mentioned *CDKN2A* deletions in PR-DLBCL at a frequency more similar to 258 PCNSL/PTLBL than an all-comer DLBCL cohort. Additionally, we observed a significant

259 impact of SCNAs on gene-expression profiles which is shown exemplarily for TSGs <sup>260</sup>(**Supplementary Figure S4**).

261

## <sup>262</sup>**Molecular clusters in primary renal DLBCL**

263 Building on our observations from WES, CNV analysis, RNA-seq, alongside structural 264 variants identified by FISH for *BCL2*, *BCL6*, and *MYC*, we performed an integrative analysis 265 on our entire cohort of PR-DLBCL samples to achieve an allocation to the previously defined 266 molecular clusters (A53, N1, BN2, EZB, and MCD) based on the probabilistic LymphGen 2.0 267. classifier  $31$ . Molecular data for an integrative analysis of sufficient sensitivity and specificity 268 was available in 30 cases. Unlike previous observations in PCNSL/PTLBL, only one case 269 resembled MCD-DLBCL. The most common molecular subtypes were ST2 (eight cases, <sup>270</sup>27%) and EZB (five cases, 17%). Of note, no double- or triple-hit lymphomas including <sup>271</sup>MYC+ EZB cases were observed. Only two cases were BN2-DLBCL (7%). While a 272 significant overlap between signatures with compound-cluster allocation was observed in 273 eight cases, six cases were found to exhibit a constellation of findings leading to a 274 classification as "other" (**Figure 1 D** and **Supplementary Table 5**).

275

#### <sup>276</sup>**Immune-escape mechanisms in primary renal DLBCL as a driver of tropism**

<sup>277</sup>Following the characterization of the mutational profiles and molecular clusters that displayed 278 the significant heterogeneity outlined above, we sought to understand the underlying 279 mechanism behind the exceptional renal tropism in our present cohort. Building on our 280 observation of a significant overlap between PR-DLBCL, PCNSL, and PTLBL, in particular 281 regarding copy number losses affecting HLA-B as a hallmark gene of MHC Class I, we 282 sought to assess the extent to which the clinical behavior of PR-DLBCL might be explained <sup>283</sup>by immune escape strategies. Integrating all available datasets, we identified deleterious <sup>284</sup>MHC Class I lesions in 72% of cases, including HLA-A and HLA-B deletions in 48% and

285 deleterious B2M mutations in 21% of evaluable patients (**Figure 5A, B**). An additional 286 fraction of 33% of patients exhibited deleterious aberrations within the MHC class II 287 machinery and 60% of patients additionally exhibited molecular hits in immediate interaction 288 partners of MHC class I or II required for adequate immune response including del 19p13.3 289 and mutations affecting CD70, CIITA, and CD58 (**Figure 5A, C**).

290 Having identified the large-scale  $6p25.2-q27$  deletion outlined above as a potential hallmark 291 of aggressive B-cell lymphomas with renal tropism, we went on to assess the transcriptional 292 profile of cases carrying said aberration and observed a significantly elevated expression of <sup>293</sup>several candidate genes (**Figure 5D** and **Supplementary Table 6**) including *CXCL10* as well 294 as strong enrichment for interferon alpha and gamma response, MYC targets, JAK/STAT <sup>295</sup>signaling, and others (**Figure 5E** and **Supplementary Table 7**). In particular, we found 296 downstream NFkB activation via TNFalpha signaling. In addition, several metabolic 297 processes including glycolysis, fatty acid metabolism, and oxidative phosphorylation appear 298 to be particularly engaged compared to non-MHC-class I-deleted cases.

299 Subsequent analysis of our cohort deconvoluting cell states and their assembly into 300 communities of co-association patterns in the form of lymphoma ecotypes (LE) employing 301 the lymphoma EcoTyper revealed a relatively diverse composition of both the tumor as well  $302$  as its microenvironment in PR-DLBCL<sup>43</sup>. Despite the limited number of cases, we observed <sup>303</sup>a trend towards enrichment in prognostically adverse ABC-DLBCL-associated lymphoma 304 ecotypes (LE) 2 and 4 dominated by B-cells, plasma cells, and dendritic cells as well as NK 305 cells, CD4 and CD8 positive T-cells alongside regulatory T-cells, respectively in del 6p25.2-306 q27 cases. Moreover, a trend towards enrichment of the T follicular helper cells dominated 307 LE5 was observed in non-del  $6p25.2-q27$  cases  $43$ . The distribution of ecotypes on cases is <sup>308</sup>depicted in **Figure 6** (**Supplementary Table 8**).

309

<sup>310</sup>**Discussion** 

311 Primary renal DLBCL poses a rare phenomenon associated with adverse clinical features and 312 outcomes, including a so far unexplained CNS tropism leading to significant mortality, 313 especially in relapsed and/or refractory cases  $6$ . This study was initiated to unravel the <sup>314</sup>molecular underpinnings of primary renal disease, to allow for an understanding as to why <sup>315</sup>and how the disease originates in an organ without a genuine lymphatic niche, and to explain 316 the clinically observed tendency of early CNS progression. To this end, we conducted an 317 integrative analysis employing WES, RNA-seq and array-based SCNV analysis on the largest 318 cohort of PR-DLBCL studied to date.

319 Hereby, we made the following noteworthy observations. First, we provide a detailed <sup>320</sup>molecular landscape of PR-DLBCL and observe a strong degree of heterogeneity in terms of 321 molecular clusters according to the LymphGen algorithm  $31$ . Contrary to our initial 322 expectation, we observed a relatively low frequency of *MYD88* mutations. Therefore only one 323 case that was allocated to the characteristic MCD cluster, which is otherwise recurrently 324 observed in both primary and secondary CNS lymphoma as well as testicular lymphoma. 325 Tropism for immune-privileged sites appears to be driven by immune escape strategies, which 326 may be augmented by activating mutations in the B-cell receptor signaling cascade  $31, 32, 44, 45$ . <sup>327</sup>Beyond this, we saw a high frequency of *SPEN* mutations previously described to be 328 associated with early progression and inferior outcome in an all-comer DLBCL cohort <sup>46</sup>. <sup>329</sup>Significant deregulation of TSGs was further validated via an integrative analysis of SCNAs 330 and transcriptional abundance. Among the genes most commonly affected by mutations 331 within our cohort, potentially targetable vulnerabilities included recurrent mutations in genes <sup>332</sup>like *EZH2* for which clinically active inhibitors have been described previously, including <sup>333</sup>combinations with BCL2 inhibitors in patients with co-occurrence of *EZH2* and *BCL2* 334 aberrations, which we observed in our cohort as well. At the same time, recurrent *CARD11* <sup>335</sup>mutations, downstream of Bruton's tyrosine kinase (BTK) may render therapeutic 336 approaches, employing BTK inhibitors inefficient in a clinically meaningful subset of patients

47-49 <sup>337</sup>. Given the peculiar tropism of PR-DLBCL, the abundance of *STAT3* mutations appears 338 striking. In addition to the known cooperative interplay between *STAT3* and the NFkB 339 signaling cascade in post-germinal DLBCL, this may further be explained as a selection 340 advantage throughout clonal evolution. In keeping with previous observations that linked <sup>341</sup>*STAT3* mutations and its elevated activity to the modulation of the abundance and function of 342 regulatory T cells in the TME of solid cancers, this suggests a therapeutical perspective 343 involving STAT3 inhibition which might be able to target the TME and its permissive impact 344 on the immunological niche in PR-DLBCL  $50, 51$ . An additional candidate driver for early 345 progression and CNS dissemination is the relatively high rate of *MYC* aberrations in more 346 than 17% of evaluable cases  $52$ .

347 Second, we describe a profile of SCNA and mutations leading to significant impairment of <sup>348</sup>MHC class I/II families and its immediately associated genes in approx. 95% of cases in the 349 cohort, which significantly exceeds observations in all-comer DLBCL cohorts  $32, 53$ . From 350 these observations, we deduce a strong overlap between PR-DLBCL and large B-cell 351 lymphomas of immune-privileged sites (IP-LBCL) regarding SCNAs. At the same time, PR-<sup>352</sup>DLBCL apparently lacks the characteristic mutational profile resulting in tonic B-cell 353 receptor signaling usually associated with this newly described entity  $1, 54$ . It is tempting to 354 speculate on a theory of a first and second hit in the central nervous dissemination of PR-<sup>355</sup>DLBCL acquiring the typical driver mutations in a second step, following the initial presence  $356$  of strong immune-escape mechanisms  $^{55}$ . To investigate this in future studies, paired analyses <sup>357</sup>of renal and CNS tumors will be required. Deleterious aberrations in MHC class I 358 components and related genes constitute well-documented phenomena in DLBCL. However, 359 the frequency at which this is observed in the present study, extending to highly recurrent 360 alterations of MHC class II genes poses a significant enrichment  $32$ . Moreover, this aligns 361 with previous observations in primary CNS lymphoma and testicular lymphoma regarding 362 deletions of the *HLA* and *CDKN2A* loci and extends well beyond previous reports in ABC-

363 DLBCL by both immunohistochemistry and gene expression profiling  $41$ . Further in keeping 364 with pathogenetically similar trajectories between PR-DLBCL and other IP-LBCL, we 365 observed 10% of cases harboring *ETV6* rearrangements previously reported as recurrent, 366 oncogenic structural variants and drivers of a post-germinal phenotype in  $PCNSL^{36}$ .

367 Third, we describe a characteristic transcriptional profile in cases harboring MHC class I 368 SCNAs as a newly described hallmark of primary renal DLBCL. It is predominantly 369 characterized by a strong enrichment for interferon alpha and gamma responses, MYC targets, 370 and JAK/STAT signaling and downstream NFkB activation via TNF-alpha signaling. All of 371 these mechanisms are known drivers, especially of ABC-DLBCL. TNF signaling was 372 recently shown to aberrantly remodel the fibroblastic reticular cell (FRC) network and 373 contribute to a tolerogenic TME hindering therapeutic efficacy of immune-based therapies <sup>51,</sup> 5<sup>56</sup>. Further, several metabolic processes including glycolysis, fatty acid metabolism, and 375 oxidative phosphorylation appear particularly engaged. This could be particularly interesting 376 in future targeted therapeutical approaches exploiting this dependence, as recently described  $57<sup>57</sup>$ . In addition, we observed a trend towards enrichment of LE2- and LE4-high states in our 378 predominantly ABC-like group of MHC class I deleted tumors, in keeping with previous 379 observations from all-comer DLBCL cohorts where these lymphoma ecotypes were 380 associated with inferior clinical outcomes  $43$ . The trend towards more LE5-high tumors in the 381 non-MHC class I deleted cases with its underlying cell states being more prevalent in healthy 382 lymphoid tissues integrates seamlessly with this notion.

383 The study presents several limitations, inherent to the retrospective design. Despite this being 384 the largest cohort of PR-DLBCL to date the sample size remains limited and samples for the 385 study were collected over more than two decades. This results in significant heterogeneity in 386 terms of first- and later-line treatment approaches and limited follow-up information. These 387 factors prohibit a meaningful integrative analysis of molecular findings and clinical 388 endpoints. In addition, there is a potential for cases with occult non-renal primary

<sup>389</sup>manifestations, which may have been missed by diagnosing physicians. However, considering 390 that secondary renal manifestations typically occur in advanced-stage disease, the likelihood 391 of a significant fraction of patients harboring secondary renal manifestations is relatively low. <sup>392</sup>In summary, we present the largest molecular study on PR-DLBCL to date, untangle the 393 genomic and transcriptional heterogeneity of the disease, and uncover evidence of significant 394 pathogenetic overlap between PR-DLBCL and IP-LBCL. Our observations may inform future 395 risk-adapted therapeutic approaches.

# <sup>397</sup>**Declarations**

# <sup>398</sup>**Ethics approval and consent to participate**

399 This retrospective study was approved by the ethics committee of the University of Lübeck <sup>400</sup>(reference-no 18-356) and conducted in accordance with the declaration of Helsinki. Patients 401 have provided written informed consent regarding routine diagnostic and academic 402 assessment, including genomic studies of their biopsy specimens alongside the transfer of 403 their clinical data.

# <sup>406</sup>**Availability of data and material**

407 Raw fastq files have been deposited in the European genome-phenome archive (EGA) under

408 the accession number EGA50000000386. OncoScan Array data has been deposited in Gene

<sup>409</sup>Expression Omnibus (GEO) under accession number GSE270422.

## <sup>411</sup>**Funding**

<sup>412</sup>This work was supported by generous funding by the Wilhelm Sander-Stiftung through a

413 project grant (NG; Grant-Nr.: 2021.150.1). HB and AK acknowledge support from the BMBF

414 project OUTLIVE-CRC (FKZ 01KD2103A).

## <sup>416</sup>**Author contributions**

- 417 Study concept: NG, ACF, HM
- 418 Data collection: NG, AK, VvK, PL, MK, HW, VB, SS, KK, HM, SS, KS, AA, ACF
- 419 Data analysis and creation of figures and tables: AK, NG, ACF, HB, NvB,
- 420 Initial Draft of manuscript: NG.
- 421 Critical revision and approval of final version: all authors.

# <sup>423</sup>**Acknowledgements**

- 424 The authors would like to thank Tanja Oeltermann for her skilled technical assistance. AK
- 425 and HB acknowledge computational support from the OMICS compute cluster at the
- 426 University of Lübeck.

# **References**

















#### **Figure Legends:**

**Figure 1. Molecular landscape of PR- DLBCL. <sup>A</sup>** Venn diagram depicting the number of samples 651 for which WES (n = 34), RNA-seq (n = 30), and OncoScan arrays (n = 29) were successfully 652 conducted. **B** Fusion identified by RNA-sequencing in PR-DLBCL samples (beyond *MYC*/*BCL2*/*BCL6* rearrangements identified in cases studied by FISH) displayed by their genomic location. **C** Sankey plot illustrating the distribution of cases of PR-DLBCL into the categories GCB/non-GCB by immunohistochemistry (IHC) according to the algorithm proposed by Hans *et al.38* 656 as well as by Cell-of-origin (CoO) classified according to gene-expression profiling derived from RNA-seq and lastly according to molecular clusters drawn from the LymphGen algorithm, integrating 658 data from WES, RNA-seq, Oncoscans, and FISH  $(BCL2/BCL6/MYC)^{31}$ , depicting the significant 659 degree of molecular heterogeneity. **D** Oncoplot displaying putative driver genes and the number of 660 samples harboring mutations in a given gene (right bar). Mutation types are color-coded, and 661 covariates, including sex, CoO, FISH results for BCL2/BCL6/MYC, and type of biopsy (punch/needle 662 core vs. open resection/nephrectomy) are shown below for each sample.

**Figure 2. Recurrently mutated putative drivers of PR-DLBCL.** Lollipop plots illustrating types and location of mutations, grouped by affected signaling pathway and/or biological function. Functional domains are depicted as a frame of reference and the lollipops' height indicates the 667 frequency with which a given mutation occurred in our cohort.

**Figure 3. Functional implication of mutations in PR-DLBCL. A** Fraction of a given pathway, biological function, or gene set impaired by mutations is depicted as the number of affected genes vs. 671 the number of genes in a given set. **B** Distribution of mutational impairment of gene sets per sample, including fraction of samples harboring one or more mutations in a given gene set.

**Figure 4. Somatic copy-number aberrations in PR-DLBCL compared with other subtypes of** 

**DLBCL including IP-LBCL. <sup>A</sup>** Location of SCNAs along the genome and GISTIC G-scores (G =

676 Frequency  $\times$  Amplitude; red bars denote gains and blue bars losses; gene names refer to affected <sup>677</sup>oncogenes and tumor suppressor genes within identified regions). **B** Tumor suppressor genes affected <sup>678</sup>by copy number losses. **C** Amplifications and deletions at recurrently affected loci in an all-comer 679 cohort of DLBCL (first column), DLBCL of ABC- as well as GCB-subtype (second and third column) 680 and IP-LBCL with primary CNS or primary testicular manifestation (column four and five) compared 681 to primary renal DLBCL (column six).

<sup>683</sup>**Figure 5. Immune escape is the predominant molecular feature of PR-DLBCL. <sup>A</sup>** Impairment of 684 the MHC class I and II apparatus as well as its immediate interaction partners by mutations and/or <sup>685</sup>SCNAs. **B, C** Lollipop plots illustrating types and location of mutations in *B2M* and *CIITA* as 686 recurrently mutated genes associated with immune escape in PR-DLBCL. Functional domains are 687 depicted as a frame of reference and the lollipops' height indicates the frequency with which a given <sup>688</sup>mutation occurred in our cohort. **D** Volcano plot illustrating results of a genome-wide screen for 689 significantly deregulated genes by the presence or absence of a large-scale deletion on chromosome 6 690 leading to strong MHC class I impairment as the most recurrent and striking feature in PR-DLBCL. <sup>691</sup>**E** Gene-set enrichment analysis depicting functional implications of deregulated gene expression 692 between cases with and without large-scale MHC class I deletions.

699

<sup>694</sup>**Figure 6. Deconvolution of PR- DLBCL transcriptomes employing the lymphoma EcoTyper. A**  695 Heatmap displaying the cell-type abundance as well as the predominant EcoType for a given PR-<sup>696</sup>DLBCL sample. **B** Comparative analysis of lymphoma EcoType abundances according to the 697 presence or absence of a large-scale deletion on chromosome 6 leading to strong MHC class I <sup>698</sup>impairment as the most recurrent and striking feature in prDLBC, grouped by lymphoma EcoTypes.

















0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 296 aa MYD88 Death TIR PIM1 0 100 200 300 400 500 600 700 770 aa STAT\_int STAT\_alpha STAT\_bind SH2



CARD1 **D** Signaling by the B-Cell Receptor BCR







**F RTK-RAS**









